Johnson & Johnson (JNJ) therapy nipocalimab granted US FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson's therapy nipocalimab receiving Fast Track designation from the FDA is a significant development for both the company and the pharmaceutical sector.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Shell (SHEL LN) CEO committed to invest BRL 3.5bln in Raizen, Brazil, according to Bloomberg TV

[MARKET UPDATE] Gilts tick higher as Reeves delivered her non-event Spring Statement, upside seen on the OBR forecasts ahead of the lower but as-expected Gilt remit

Johnson & Johnson (JNJ) therapy nipocalimab granted US FDA Fast Track designation in systemic lupus erythematosus (SLE)

UK OBR Forecasts:

UK DMO Remit: 2026/27 Gilt issuance of GBP 252.1bln (exp. c. 250bln, prev. 303.7bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This expedited status can enhance the drug's market potential, possibly leading to earlier commercialization, positively impacting JNJ’s stock performance and boosting sentiment in biopharma stocks as well.

Related headlines

The whole workspace, free to try.

Try it free